RxDoctor Payments DataLook up a doctor →

Louis Varner, MD

Hematology & Oncology · Hattiesburg, MSNPI 1669682134

Payments from drug & device makers

$9,862in general payments, 2019–2025

Across 497 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$889
  • Merck$618
  • Novartis$502
  • AstraZeneca$453
  • Incyte Corporation$452
  • Daiichi Sankyo Inc.$444
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)44$889
Merck30$618
Novartis28$502
AstraZeneca(2 entities)26$453
Incyte Corporation25$452
Daiichi Sankyo Inc.18$444
Bristol Myers Squibb18$338
Pfizer17$310
Gilead(2 entities)13$300
Lilly USA, LLC13$298
Genentech USA, Inc.17$292
Seagen Inc.6$267
Astellas Pharma US Inc15$263
Sanofi14$256
E.r. Squibb & Sons, L.L.C.12$241
Bayer12$203
Genmab U.S., Inc.7$198
Exelixis Inc.8$188
Eisai Inc.10$176
Amgen10$175
AbbVie8$169
Regeneron Healthcare Solutions, Inc.7$168
Puma Biotechnology, Inc.11$147
GSK7$134
Pharmacyclics LLC, An Abbvie Company5$127
Beigene USA, Inc.6$123
EMD Serono, Inc.6$122
Jazz Pharmaceuticals Inc.5$116
Stemline Therapeutics Inc.5$109
ADC Therapeutics America, Inc.4$103
Tersera Therapeutics LLC4$102
Pharmacosmos Therapeutics Inc.5$96
Deciphera Pharmaceuticals Inc.4$89
Octapharma USA, Inc.4$89
Ipsen Biopharmaceuticals, Inc5$77
Rigel Pharmaceuticals, Inc.5$77
Takeda Pharmaceuticals U.S.A., Inc.5$75
Beone Medicines USA, Inc.3$68
Spectrum Pharmaceuticals Inc.2$65
Sobi, Inc3$65
G1 Therapeutics, Inc.4$64
Fresenius Kabi USA, LLC3$62
AVEO Pharmaceuticals, Inc.3$58
Verastem, Inc.4$57
Springworks Therapeutics, Inc.3$53
Tesaro, Inc.3$49
Pharmaessentia USA Corporation2$45
Karyopharm Therapeutics Inc.2$45
Foundation Medicine, Inc.2$35
Boehringer Ingelheim2$35
Blueprint Medicines Corporation2$33
Sanofi-aventis U.S. LLC2$33
Morphosys, US Inc.2$27
Legend Biotech USA Inc.1$25
Adaptive Biotechnologies Corporation1$23
Progenics Pharmaceuticals, Inc.1$22
Taiho Oncology, Inc.1$21
CTI Biopharma Corp.1$21
Janssen Scientific Affairs, LLC1$19
Shield Therapeutics Inc1$17

How this compares

$9,862 in reported general payments places this provider in the 40th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi →

Medicare billing

Part B allowed, 2024
$3,277,773
Medicare patients
336
Services billed
117,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hattiesburg

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →